What MedAccess does

MedAccess is a UK-based not-for-profit social enterprise founded in 2017 and headquartered in London that brokers and finances agreements to accelerate access to medical innovations in low- and middle-income countries. Its core capability is not technology development but financial structuring: volume guarantees that provide manufacturers with demand visibility and risk-sharing to enable price reductions; working capital facilities that help companies scale production; and procurement guarantees that accelerate bulk purchasing by global health agencies. MedAccess is wholly owned by British International Investment (BII), the UK's development finance institution, which has provided $170 million of paid-in capital against a $200 million authorized capitalization. An additional €52 million counter-guarantee from the European Investment Bank (announced 2025) extends its risk-absorbing capacity.

The company's products take the form of deal-based agreements with manufacturers such as Hologic (viral load testing at $12 ceiling price), BASF (Interceptor G2 mosquito nets, 40% price reduction), dsm-firmenich (vitamin A ceiling pricing), Elekta (pay-per-use radiotherapy), SD Biosensor, Wondfo, Macleods, Viatris, Hewatele, and Synergy. These agreements are operationalized through implementation partners including CHAI, PATH, UNICEF, Gavi, the Global Fund, Unitaid, and IVCC. Reported outcomes include 559 million people reached across 115+ countries, $217 million saved for procurers, and notable price reductions across HIV self-tests ($1), 3HP TB preventive therapy ($14.25 per course), and pretomanid (34% reduction).

MedAccess's business model is grant-and-fee funded rather than transaction-based. Revenue streams include fees for access to its financial tools, grant funding from institutional donors (UK FCDO has provided £17 million since 2021 under the Global Fund Accelerator, Gates Foundation, Wellcome, and EIB), and any operational surpluses are reinvested into new agreements under its not-for-profit mandate. The company does not sell products directly; goods reach patients through national health systems and procurement channels managed by global health partners. Geographic focus is concentrated on OECD-DAC-eligible countries with at least 50% of patients in BII priority territories (sub-Saharan Africa and South Asia).

Name

MedAccess

Legal name

MedAccess Guarantee Ltd

Website

https://medaccess.org

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

MedAccess is a UK not-for-profit social enterprise founded in 2017 that uses volume guarantees, working capital facilities, and procurement guarantees to accelerate affordable access to medical innovations in low- and middle-income countries, backed by British International Investment.

Ownership category

akta.pro rank

Product category

Global Health Financing

NAICS

Voluntary Health Organizations (813212)

SIC

Services-Health Services (8000)

akta.pro primary industry

Global Supply Chain, Procurement & Market-Shaping Partnerships (Medicines/Diagnostics/Vaccines) (HLAJAOAK)

akta.pro secondary industries

Tender & Public Procurement Pricing (Hospital/Regional/National Tenders) (HLAIAKAJ), Pricing & Contracting Strategy (HLAIAKAA), Vaccine Procurement, Tendering & Immunization Supply Programs (HLAIAEAN)

Keywords

• Innovative health finance
• Market shaping agreements
• Volume guarantee financing
• Global health access
• Social impact finance

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Others, Marketing or Sales, Technology or R&D

Revenue model

1. Financial tool access fees: MedAccess charges fees for access to their financial tools. This income covers partnership implementation and monitoring costs. As a not-for-profit social enterprise, any operational surpluses are reinvested into developing new agreements to accelerate access to healthcare.
2. Grant funding: MedAccess receives grant funding from institutional donors including UK Foreign Commonwealth & Development Office (FCDO), Gates Foundation, and Wellcome to cover scoping, negotiating, and executing financing agreements. Since 2021, FCDO has provided £17 million in grant funding as part of its Global Fund Accelerator programme.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

MedAccess brokers and structures innovative financing agreements — volume guarantees, working capital facilities, and procurement guarantees — between medical product manufacturers and global health procurement organizations. These agreements reduce prices, secure supply, and accelerate access to medical innovations (diagnostics, treatments, vaccines, devices) for low- and middle-income countries. Operational outcomes include a $12 ceiling price per viral load test, a $1 HIV self-test, a 40% mosquito net price reduction, and a 34% pretomanid price reduction.

Differentiator

Problem solved

Functional benefit

Brands

• MedAccess Trust: Established in 2021 to receive and provide stewardship for grants from funders seeking to increase access to healthcare in low- and middle-income countries.

Products and services

• Volume guarantees
• Working capital facilities
• Procurement guarantees

Quantifiable outcome

• 559 million people reached with MedAccess-supported products
• +5 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

20 partnerships are on record, tiered core and minor.

• Clinton Health Access Initiative (CHAI)coreImplementation/ SI/ Consulting PartnerMedAccess has partnered with CHAI to increase access to a range of health products including HIV viral load testing, 3HP latent TB treatment, a dual test for HIV and syphilis, and HIV self-tests. CHAI is a key implementation partner in multiple agreements.
• Gavi, the Vaccine AlliancecoreStrategic or Co-development PartnerMedAccess' financing agreement with GSK and Gavi enabled continued production of RTS,S malaria vaccine antigen ahead of key policy and funding decisions. Also provided guarantee for COVAX efforts to increase access to COVID-19 vaccines.
• UNICEFcoreImplementation/ SI/ Consulting PartnerPartnership accelerated access to vital COVID-19 and non-COVID-19 medical products, reducing country waiting times for supplies by up to seven months. MedAccess provided $50M procurement guarantee for UNICEF's Vaccine Independence Initiative.
• Global FundcoreStrategic or Co-development PartnerMedAccess guarantees help make HIV, TB and malaria products more affordable, enabling the Global Fund to reach more people in need. FCDO support has unlocked additional value for Global Fund investments.
• HologiccoreStrategic or Co-development PartnerVolume guarantee for Hologic increased access to viral load testing using the Panther platform by agreeing an all-inclusive $12 ceiling price per patient test. First agreement announced July 2018 at AIDS 2018 conference.
• BASFcoreStrategic or Co-development PartnerVolume guarantee to BASF reduced price of at least 35 million next-generation Interceptor G2 mosquito nets to prevent malaria. Net price reduced by 40%, with over 41 million nets shipped to 19 African countries.
• dsm-firmenichcoreStrategic or Co-development PartnerMedAccess partnered with dsm-firmenich to provide stable pricing and sustainable supply of vitamin A for edible oil fortification. MedAccess provides volume guarantee enabling ceiling prices of $59/kg for vitamin A and $43.30/kg for vitamin A/D3 blend.
• ElektacoreStrategic or Co-development PartnerMedAccess provided volume guarantee to Elekta to deliver innovative pay-per-use model for radiotherapy treatment in Kenya and Tanzania. Reduces upfront capital commitment for governments and improves procurement transparency.
• SD BiosensorcoreStrategic or Co-development PartnerVolume guarantees helped SD Biosensor increase access to dual testing for syphilis and HIV, and G6PD testing devices and strips to tackle P. vivax malaria. Dual test price reduced to under $1 per test.
• WondfocoreStrategic or Co-development PartnerVolume guarantee enabled price reduction for WHO prequalified HIV self-test to $1, accelerating access for more people at risk of HIV.
• MacleodscoreStrategic or Co-development PartnerVolume guarantee for Macleods increased supply security, affordability and availability of 3HP short-course TB preventive therapy. Price reduced from $40 to $14.25 per patient course.
• ViatriscoreStrategic or Co-development PartnerPartnership with Viatris reduced price of pretomanid, a drug used as part of new treatment regimen for drug-resistant tuberculosis, by 34% in over 130 low- and middle-income countries.
• TB AlliancecoreStrategic or Co-development PartnerMedAccess partners with TB Alliance to support introduction and scale up of new regimens to treat multidrug-resistant TB, including the BPaLM regimen.
• PATHcoreImplementation/ SI/ Consulting PartnerMedAccess works with PATH to accelerate access to SD Biosensor's G6PD testing devices and strips. PATH is also implementation partner in East Africa Programme on Oxygen Access.
• HemexcoreStrategic or Co-development PartnerMedAccess provided $2.5 million working capital facility to Hemex to enable scaling of portable Gazelle sickle cell disease testing platform in India, Africa and Middle East.
• HewatelecoreStrategic or Co-development PartnerMedAccess partnering with Kenyan oxygen supplier Hewatele to increase access to locally produced oxygen as part of East Africa Programme on Oxygen Access (EAPOA). Volume guarantee sets ceiling price of KSH 165 ($1.27)/kg.
• SynergycoreStrategic or Co-development PartnerMedAccess partnered with Kenyan oxygen supplier Synergy to increase access to locally produced oxygen as part of EAPOA. Agreement provides oxygen at ~25% below current market prices.
• UnitaidcoreStrategic or Co-development PartnerMedAccess works with Unitaid to shape markets for interventions against malaria and TB, including mosquito nets and latent TB treatment. EAPOA is funded by Unitaid with contributions from Canada and Japan.
• IVCCminorImplementation/ SI/ Consulting PartnerIVCC partnered with BASF to support development of Interceptor G2 mosquito nets and is lead implementer in New Nets Project funded by Global Fund and Unitaid.
• Access to Medicine FoundationminorStrategic or Co-development PartnerIndependent research foundation that encourages healthcare companies to improve access to their products.

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/medaccessuk
• YouTubeyoutube.com/@MedAccessUK
• LinkedInuk.linkedin.com/company/medaccess-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles25 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MedAccess